Cite
HARVARD Citation
Gabay, C. et al. (n.d.). LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial. Annals of the rheumatic diseases. p. 152. [Online].